Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

Exclusion Criteria

• •1. Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of \<1%) from 2 weeks prior to dosing until the end-of-study visit.
• •2. Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocol
• •3. History of or current clinically significant disease as defined in the protocol.
• •4. History of GERD, significant acid reflux.
• •5. Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit).